

CURRICULUM VITAE

PATRICK THOMAS SCHUETTE, MD, FACP

Illinois Bone and Joint Institute, LLC, Clinic Locations:

2101 Waukegan Road Suite 110 Bannockburn, IL 60015 Phone: (847) 914-9096 Fax: (847) 914-9009	9000 Waukegan Road Morton Grove, IL 60053 Phone: (847) 375-3000 Fax: (847) 929-1190 E-mail: pschuetter@ibji.com
--	---

PROFESSIONAL EXPERIENCE

- 1/01-Present Rheumatologist, Illinois Bone & Joint Institute, LLC, Chicago, IL
Practice clinical rheumatology; teach medical students and residents from affiliated hospitals. Specialist in osteoporosis, back pain, epidural steroid injection, rheumatoid arthritis, ultrasound.
- 1999-Present Director, Division of Rheumatology, Advocate Lutheran General Hospital, Park Ridge, IL
- 1981-Present Assistant Professor – Clinical Medicine, Northwestern University Medical School, Chicago, IL
- 1999-2001 Co-Director – Osteoporosis Center, Advocate Medical Group, Park Ridge, IL
- 1989-1/01 Rheumatologist – Lutheran General Medical Group/Advocate Medical Group, Niles, IL
- 1979-1989 Rheumatologist – Private Practice, Chicago, IL
- Chief of Rheumatology
1985 – 2001 Ravenswood Hospital, Chicago, IL
1985 – 1999 Weiss Hospital, Chicago, IL
1981 – 1991 Grant Hospital, Chicago, IL
1979 – 1985 Columbus Hospital, Chicago, IL

EDUCATION

- 1966-1970 B.A., History, Yale University, New Haven, CT
- 1970-1973 M.D., Medical University of South Carolina, Charleston, SC

POSTGRADUATE MEDICAL TRAINING

- 1/74 – 6/74 Internship (Neurology)
Medical University of South Carolina, Charleston, SC
- 1974-1977 Residency (Internal Medicine)
University of Illinois, Chicago, IL
- 1977-1979 Fellowship (Rheumatology)
Northwestern University Medical School, Chicago, IL

FACULTY APPOINTMENTS

- 1978-1981 Instructor of Clinical Medicine
Feinberg School of Medicine, Northwestern University, Chicago, IL

1981-Present Assistant Professor of Clinical Medicine
Feinberg School of Medicine, Northwestern University, Chicago, IL
2003-Present Instructor of Clinical Medicine
Finch School of Health Sciences, The Chicago Medical School, No. Chicago, IL

MEDICAL LICENSURE

1973-Present Illinois Medical License and DEA Registration

HOSPITAL APPOINTMENTS

1977-Present Consulting Member Medical Staff
Northwestern Memorial Hospital, Chicago, IL

1985-2001 Director of Rheumatology Attending Medical Staff
Ravenswood Hospital, Chicago, IL

1989-Present Attending Medical Staff
Advocate Lutheran General Hospital, Park Ridge, IL

1999-Present Advocate Illinois Masonic Hospital, Chicago, IL

2001-2003 Holy Family Hospital, Des Plaines, IL

2003-Present Evanston Northwestern System, Evanston, IL

BOARD CERTIFICATIONS

1997 Certified – Illinois Society for Clinical Densitometry
Re-Certified 2001 and 2002
1980 Subspecialty Board of Rheumatology
1977 American Board of Internal Medicine
1975 National Board of Examiners

PROFESSIONAL ASSOCIATIONS

Fellow - American College of Physicians
Fellow - American College of Rheumatology
Chicago Rheumatism Society
International Society of Clinical Densitometry
American Institute of Ultrasound Medicine
International Society for Extremity MRI in Rheumatology

PUBLICATIONS

Kar, P, Aronoff, G, **Schuetz, P**: "Bronchopulmonary Disease: An Association With Ulcerative Colitis and Pyoderma Gangrenosum" *KMA Journal*, Vol 91: 320-322, 1993.

Hughes S, Edelman P, Chang R, Naughton R, Singer R, **Schuetz PT**, Liang G: "Validity of self-reported prevalence of musculoskeletal conditions in the elderly" *American Journal of Public Health*.

Hughes S, Edelman P, Chang R, Naughton R, Singer R, **Schuetz PT**, Liang G, "Estimates and determinants of valid self-reports of musculoskeletal disease in the elderly". *Journal of Aging and Health*, Vol 5, No. 2 244-263, 1993.

Hughes S, Edelman P, Chang R, Singer R, **Schuetz PT**: "Their GERI-AIMS scales for the elderly. Reliability and Validity". *Arthritis and Rheumatism*, 34: 856,1991.

Hughes S, Edelman P, Chang R, Singer R, **Schuetz PT**. "The revised arthritis impact measurement scales for the elderly: new validity and reliability finding". *Arthritis and Rheumatism, (Supplement)*. 31 (4): S76, 1988.

Hughes S, Chang R, Edelman P, Blandford G, Berg L, Singer R, **Schuette PT**. "Use and measurement properties of the revised arthritis impact measurement scales for the elderly". *Arthritis and Rheumatism, (Supplement)*. 30: S101,1987.

Hughes S, Chang R, Blandford G, Berg L, Edelman P, Singer R, **Schuette PT**. "Musculoskeletal disease in the elderly: prevalence and associated functional impairment". *Arthritis and Rheumatism, (Supplement)*. 29: 147, 1986.

Schuette, PT: "The recurrent joint pain questionnaire". Presented at International Symposium on the Epidemiology of Rheumatic Diseases in Industrial Labor. Hamburg, West Germany, June 1985.

Arnold W, Stulberg SD, **Schuette PT**, Schmidt FR. "Intraarticular soft tissue abnormalities are a frequent finding associated with chronic pain. Patients with early Osteoarthritis of the knee". *Arthritis and Rheumatism, (Supplement)*. 27, 1984.

Wells JS, Zipp FJ, **Schuette PT**, MeElency J. "Musculoskeletal disorders among letter carriers. A comparison of weight carrying, walking and secondary occupations". *Journal of Occupational Medicine*, 25 (11): 814, 1983.

Green D, **Schuette PT**, Wallace WH: "Factor VIII antibodies in rheumatoid arthritis: The effect of antibodies in rheumatoid arthritis: the effect of cyclophosphamide". *Archives of Internal Medicine*, 140: 1232,1980.

Schuette PT, Schmid FR. "Arthritic syndromes associated with enteropathies". *Clinical Medicine*, Harper and Row Publishers, 1980.

Schuette PT, Brabham AM, Eurenious K. "Thrombotic thrombocytopenia purpura: A re-evaluation". *Southern Medical Journal*, 67: 915, 1974.

RESEARCH STUDIES

PRINCIPAL CLINICAL INVESTIGATOR

Smith & Nephew, Inc., Orthopaedic Division, Memphis, TN

- A Non-significant Risk Investigational Device Exemption Clinical Study to Evaluate the Safety and Effectiveness of the Resonance Platform in Treating Post-Menopausal Osteopenic Women. May 03, 2002
- Principal Clinical Investigator
 - Planned Study
 - Designed protocol to clinical aspects of study
 - Set control group, inclusion/exclusion criteria and clinical end points
 - Testified before FDA panel

PRIMARY INVESTIGATOR

AFP A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Dose Levels (2.5, 7.5 and 20 mg) of MM-093 in Patients with Active Rheumatoid Arthritis on Stable Doses of Methotrexate. Funded by: Merrimack

OA Knee A Randomized, Double-Blind, Placebo- and Positive-Controlled, Parallel- Group, Multicenter Study of Oral Doses of CJ-023, 423 Administered for 4 Weeks to Subjects With Osteoarthritic Pain of the Knee. Funded by: Pfizer

OLE An Open-Label, Multi-Center, Long-Term Extension Study to Assess the Safety, Tolerability and Effect on disease Status of MM-093 Treatment in Subjects With Rheumatoid Arthritis Who Completed Prior Studies on MM-093. Funded by: Merrimack

Radius Rheumatoid Arthritis DMARD Intervention and Utilization Study. Funded by: Amgen

Radius-2 Rheumatoid Arthritis DMARD Intervention and Utilization Study (Radius 2). Funded by: Amgen

CO-INVESTIGATOR

Enbrel Open-label study to assess the safety and immunogenicity of etanercept serum-free process when administered to subjects diagnosed with rheumatoid arthritis. Funded by: Amgen

A6341008 A 2-week, randomized, double-blind, placebo- and positive-controlled, parallel-group, multicenter study of CE-224,535 in subjects with osteoarthritic pain of the knee. Funded by: Pfizer

ALZA A phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel group study of RWJ-445380 cathepsin-S inhibitor in patients with active rheumatoid arthritis despite Methotrexate therapy. Funded by: Johnson & Johnson

ZOL A one-year partial double-blinded, randomized, multi-center, multi-national study to assess the effects of combination therapy of annual Zoledronic acid (dmg) and daily subcutaneous Teriparatide (20 mcg) on postmenopausal women with severe osteoporosis. Funded by: Novartis

Kynetic-2 Duloxetine 60 to 120 mg versus placebo in the treatment of patients with osteoarthritis knee pain. Funded by: Eli Lilly

GEL 200 A multi-center, randomized, double-blind, controlled, parallel-group study of a single intra-articular injection of GEL-200 with a single intra-articular injection of phosphate buffered saline (PBS) in osteoarthritis of the knee. Funded by: Averion

Supartz A multicenter, randomized, double-blind, placebo controlled trial of three injections of SUPARTZ (sodium hyaluronate) for the treatment of chronic shoulder pain associated with glenohumeral osteoarthritis. Funded by: Smith & Nephew

Stage A randomized, double-blind, parallel group, international, study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing Methotrexate treatment. Funded by: Genentech

Script A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-therapy. Funded by: Genentech

GEL/1132 A multi-center, extension and open-label study of a single or repeat intra-articular injection of Gel-200 in osteoarthritis of the knee. Funded by: Averion

Act A Multi-Center Study of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab (DE7) in Subjects with Active Rheumatoid Arthritis. Funded by: Abbott

Archer A randomized, double-blind, double-dummy, parallel group study to determine the efficacy and safety of RO4402257 monotherapy in comparison to methotrexate monotherapy in patients with active rheumatoid arthritis (RA). Funded by: Roche

FIBROmyalgia - A 13-week, randomized, double-blind, placebo-controlled trial of Pregabalin twice daily in patients with Fibromyalgia. Funded by: Pfizer

HERO Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO). Funded by: Abbott

HIP 2367 A 13-Week, Multicenter, Randomized, double-Blind, double-Dummy, Placebo-controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients with primary Hip Osteoarthritis Using Celecoxib (200 mg o.d.) as a Positive Control. Funded by Novartis

Low Back Pain - A Six Week Double-Blind, Randomized, Multicenter Comparison Study of the Analgesic Effectiveness of Celecoxib 200 mg BID Compared to Tramadol Hydrochloride 50 mg QID in Subjects with Chronic Low Back Pain. Funded by: Pfizer

GHCY The Effect of Teriparatide Compared with Risedronate on Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures. Funded by: Eli Lilly

MRA–Ambition - A randomized, double-blind, double-dummy, parallel group study determining the effect of MRA as a monotherapy by comparing it with a regimen of methotrexate (MTX) alone, in patients with active rheumatoid arthritis who have not been treated with MTX within 6 months of randomization. Funded by: Roche

MRA Extension - Long-term extension study of safety during treatment with Tocilizumab (MRA) in patients completing treatment in MRA core studies. Funded by: Roche

Naïve A prospective, open-label, multicenter study to evaluate the change in bone turnover markers after once monthly oral Ibandronate therapy in treatment naïve postmenopausal osteoporosis patients. Funded by: Roche

Ovation A Multicenter, Parallel, Double-Blind, Masked-Observer, Randomized Comparison of the Efficacy and Safety of Synvisc (hylan G-F 20) and Depo-Medrol (methylprednisolone acetate) in Patients with Mild to Moderate Primary Osteoarthritis of the Hip. Funded by: Genzyme

Medal A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis or Rheumatoid Arthritis. Funded by: Merck

E-Force A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, Study to evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg Patients With Osteoarthritis of the Knee. Funded by: Merck

Edge-2 A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg Q.D. Versus Diclofenac Sodium 75 mg B.I.D. in Patients With Rheumatoid Arthritis. Funded by: Merck

EXCCEL1 A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, parallel-Group, Double-Blind, 2-Part Study to assess the safety and Efficacy of Etoricoxib 30 mg vs. Celecoxib 200 mg in Patients With Osteoarthritis (Study 1). Funded by: Merck

Edge A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg O.D. vs. Diclofenac Sodium 50 mg T.I.D. in Patients with OA. Funded by: Merck

Prograf	A randomized, Double-Blind study to assess the Efficacy of Tacrolimus (Prograf) + Methotrexate vs. Placebo + Methotrexate in the Treatment of Rheumatoid Arthritis in Patients with Partial Response to Methotrexate. Funded by: Fujisawa
PRESTO	A 52-week, international, Multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of lumiracoxib 100mg od, lumiracoxib 100mg bid and Celecoxib 200mg od in patients with primary Osteoarthritis of hip, knee, hand or spine. Funded by: Novartis
Apex	A Phase III Randomized, Multicenter Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects with Gout. Funded by: TAP
EXEL	A Phase 3, Open-Label Study, Randomized, Allopurinol-Controlled Study to assess the Long-Term Safety of Oral Febuxostat in Subjects with Gout. Funded by: TAP
EMBARK	A Phase 4, Open-Label, single-Arm, Observational Study Evaluating the Effectiveness and Safety of Enbrel (etanercept) 50 mg Once Weekly in Rheumatoid Arthritis subjects who Have Failed Remicade (infliximab). Funded by: Amgen
Celebrex	A Double-Blind, Placebo Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) vs. Placebo in the Treatment of Subjects with Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen (Protocol A3191082). Funded by: Pfizer
Amflex	A Multicenter, Randomized, Active-controlled, single-blind, Parallel-group Comparison of Risedronate 5mg Flexible-dosing Instructions to Before-breakfast dosing Instructions in Postmenopausal Women with Osteoporosis. Funded by: Aventis
Bones	Double-Blind, Placebo controlled, Dose Ranging Trial to Evaluate the Efficacy of Atorvastatin on Bone Mineral Density and Markers for bone Turnover in Postmenopausal Women with Dyslipidemia and at Risk for Osteoporosis. Funded by: Pfizer
Activate	A Randomized Multicenter Parallel Group Study to Determine if Knowledge of Baseline Vertebral Fracture Prevalence (As Determined by Hologic IVA) and Bone Turnover Marker Levels Improves Persistence with Actonel 5 mg Daily Therapy in Subjects Receiving Chronic Glucocorticoid Therapy. Funded by: Aventis
FACT	A Randomized, double-Blind, double-Dummy, Parallel-Group, Multicenter Study to Evaluate and compare the Effects of Once Weekly Alendronate and Risedronate on bone Mineral Density in Postmenopausal Women with Osteoporosis. Funded by: Merck
4001 Prevention	– A One-year, Multicenter, Randomized, double-blind, Placebo-controlled, Parallel Group Study to Determine the Efficacy And Safety Of 35-mg Risedronate Administered Once a Week in the Prevention of Osteoporosis in Postmenopausal Women. Funded by: Aventis
Oasis	A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Compare the Safety and Tolerability of an Oral Buffered Solution of Alendronate Sodium

70 mg Once Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women. Funded by: Merck

Pearl Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene. Funded by: Merck

FACT Extension – A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on bone Mineral Density in Postmenopausal Women with Osteoporosis (FOSAMAX ACTONEL Comparison Trial – FACT). Funded by: Merck

Horizon Multinational, Multicenter double-blind, randomized, placebo controlled, parallel group study assessing the efficacy of intravenous zoledronic acid in preventing subsequent osteoporotic fracture after a hip fracture. Funded by: Novartis

DANCE FORTEO Observational Study. Funded by: Eli Lilly

Foundation Effects of Arzoxifene on bone Mineral Density and Endometrial Histology in Postmenopausal Women. Funded by: Eli Lilly

WJA A Study to Evaluate biochemical Markers Associated With Osteoarthritis (OA) Disease Activity in OA Patients Compared to Age and Gender Matched Controls. Funded by: Pfizer